This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nozawa, S. Articles by Mochizuki, H. Search for Related Content PubMed PubMed Citation Articles by Nozawa, S. Articles by Mochizuki, H.

CA54/61 as a Marker for Epithelial Ovarian Cancer

Department of Obstetrics and Gynecology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160 [S. N., D. A., M. Y., K. T., T. K.]; Department of Obstetrics and Gynecology, The Jikei University School of Medicine, 3-25-8 Nishi-Shinbashi, Minato-ku, Tokyo 105 [E. K., Y. T.]; Department of Obstetrics and Gynecology, School of Medicine, Chiba University, 1-8-1 Inohana, Chiba-shi, Chiba 280 [N. I., H. T.]; Department of Obstetrics and Gynecology, Tokyo Medical College, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160 [Y. N.]; Department of Internal Medicine, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104 [H. O.]; and Laboratories for Bioscience, Mochida Pharmaceutical Co., Ltd., 1-1-1 Kamiya, Kita-ku, Tokyo 115 [H. S., H. M.], Japan

Using a new one-step, double-determinant enzyme immunoassay, we performed quantitative measurements of a mucin-type glycoprotein antigen (CA54/61) that we recently detected in sera of ovarian carcinoma patients. When the cutoff value was set at 12 units/ml, at which a high diagnostic efficiency was demonstrated [or at 20 units/ml (mean + 3 SD of healthy females)], the positive rates of ovarian serous, mucinous, clear cell, and endometrioid carcinomas were 76% (or 63%), 63% (or 55%), 57% (or 52%), and 50% (or 38%), respectively. Even in mucinous cystadenocarcinoma, more than one-half of the cases were positive, indicating the potential utility of the assay in the diagnosis of mucinous tumors. In sera from patients with benign ovarian tumors, only 9% (or 4%) of the cases were positive, indicating the quite high specificity of this test for ovarian carcinomas. To make a comparison between CA54/61 and CA125, we set the cutoff level of CA125 at 110 units/ml, at which value a high diagnostic efficiency was demonstrated [or at 35 units/ml (mean + 3 SD of healthy females)]. When both CA54/61 and CA125 were assessed in sera from 36 patients with mucinous cystadenocarcinoma, the positive rates of CA54/61 and CA125 were 64% (or 56%) and 36% (or 56%), respectively, suggesting that CA54/61 is of clinical value as a new tumor marker for ovarian cancers, including mucinous tumors.

¹ To whom requests for reprints should be addressed.

Received 9/18/91. Accepted 12/17/91.

This article has been cited by other articles:

				P. J. Tebben, K. R. Kalli, W. A. Cliby, L. C. Hartmann, J. P. Grande, R. J. Singh, and R. Kumar Elevated Fibroblast Growth Factor 23 in Women With Malignant Ovarian Tumors Mayo Clin. Proc., June 1, 2005; 80(6): 745 - 751. [Abstract] [PDF]

				M.F. Vine Biological Markers: Their Use in Quantitative Assessments Advances in Dental Research, June 1, 1994; 8(1): 92 - 99. [Abstract] [PDF]